- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05832879
Telehealth Treatment for Opioid Use Disorders
A Pilot Study of Telehealth Treatment for Opioid Use Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to assess effects of enrollment in a comprehensive telehealth platform, in adults with moderate or severe opioid use disorder with a history of at least one opioid overdose. Thirty adults with moderate or severe opioid use disorder with a history of at least one opioid overdose will be enrolled and the primary endpoint will be attendance at first appointment for medication for opioid use disorder at 30 days.
Secondary aims include assessing engagement in the first MOUD appointment at 90 days and self-report of the number of subsequent overdose events at 30 and 90 days. Exploratory aims include feasibility of intervention, readiness and intention to engage in treatment, acceptability and satisfaction of intervention, and comparison of MOUD engagement with data from previous in-person studies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rebekah Heckmann, MD, MPH, MPA
- Phone Number: (203) 737-8335
- Email: rebekah.heckmann@yale.edu
Study Contact Backup
- Name: Michael Pantalon, PhD
- Phone Number: (203) 785-4363
- Email: michael.pantalon@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Can speak, read and write in English
- Provision of signed and dated informed consent form
- Have a history of at least one opioid overdose
- Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
- Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
- Can provide a working email address OR be willing to create one
Exclusion Criteria:
- Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
- Pregnancy or lactation
- Known current suicide risk based on participant self-report
- On parole or incarcerated at time of enrollment based on participant self-report
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OUD Telehealth Platform
Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.
|
The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attendance for MOUD
Time Frame: Up to 30 Days
|
Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.
|
Up to 30 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement with MOUD
Time Frame: Up to 90 days
|
Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral.
|
Up to 90 days
|
Overdose Events at 30 Days
Time Frame: Up to 30 days
|
A self-report of the number of subsequent overdose events at 30 days.
|
Up to 30 days
|
Overdose Events at 90 Days
Time Frame: Up to 90 days
|
A self-report of the number of subsequent overdose events at 90 days.
|
Up to 90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rebekah Heckmann, MD, MPH, MPA, Yale School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000034414
- 1R61DA057675-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use Disorder
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on OUD Telehealth Platform
-
Banner HealthUniversity of Pennsylvania; National Institute on Aging (NIA)Not yet recruiting
-
Northwell HealthGary and Mary West Health InstituteCompletedCaregiver Stress | Satisfaction, ConsumerUnited States
-
See Yourself Health LLCUniversity of LouisvilleNot yet recruiting
-
Medical University of South CarolinaCompleted
-
University of PittsburghCompletedPregnancy Related | Opioid-use DisorderUnited States
-
Biomedical Development CorporationCompleted
-
University of Alabama at BirminghamThe Craig H. Neilsen Foundation; Lakeshore FoundationCompletedSpinal Cord InjuriesUnited States
-
Vanderbilt University Medical CenterNational Center for Complementary and Integrative Health (NCCIH)RecruitingChronic Low-back Pain | Postsurgical Pain | Lumbar Spine SurgeryUnited States
-
University of Southern DenmarkOdense University Hospital; Sygekassernes Helsefond; Danish Nurses OrganisationCompleted